Works matching DE "VENETOCLAX"
Results: 489
Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 231, doi. 10.1007/s00277-025-06196-2
- By:
- Publication type:
- Article
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 829, doi. 10.1007/s00277-024-06118-8
- By:
- Publication type:
- Article
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 489, doi. 10.1007/s00277-024-06110-2
- By:
- Publication type:
- Article
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 285, doi. 10.1007/s00277-024-06048-5
- By:
- Publication type:
- Article
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 307, doi. 10.1007/s00277-024-05976-6
- By:
- Publication type:
- Article
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 63, doi. 10.3390/curroncol32020063
- By:
- Publication type:
- Article
维奈克拉联合阿扎胞苷对老年急性髓系白血病患者 T 淋巴细胞亚群的 影响及其疗效的影响因素分析.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 22, p. 4389, doi. 10.13241/j.cnki.pmb.2024.22.057
- By:
- Publication type:
- Article
Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter's syndrome.
- Published in:
- Oxford Medical Case Reports, 2022, v. 2022, n. 10, p. 1, doi. 10.1093/omcr/omac111
- By:
- Publication type:
- Article
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01145-0
- By:
- Publication type:
- Article
Current status and research directions in acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01143-2
- By:
- Publication type:
- Article
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.
- Published in:
- 2024
- By:
- Publication type:
- Letter
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity "graft-versus-leukemia effects".
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01064-0
- By:
- Publication type:
- Article
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01000-2
- By:
- Publication type:
- Article
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00982-3
- By:
- Publication type:
- Article
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00964-x
- By:
- Publication type:
- Article
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00962-z
- By:
- Publication type:
- Article
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00948-x
- By:
- Publication type:
- Article
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00928-1
- By:
- Publication type:
- Article
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
- By:
- Publication type:
- Article
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00911-w
- By:
- Publication type:
- Article
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00870-2
- By:
- Publication type:
- Article
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00871-1
- By:
- Publication type:
- Article
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 12, p. 1, doi. 10.1038/s41408-022-00770-x
- By:
- Publication type:
- Article
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00744-z
- By:
- Publication type:
- Article
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00710-9
- By:
- Publication type:
- Article
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00670-0
- By:
- Publication type:
- Article
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00668-8
- By:
- Publication type:
- Article
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00604-2
- By:
- Publication type:
- Article
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00603-3
- By:
- Publication type:
- Article
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 10, p. 1, doi. 10.1038/s41408-021-00555-8
- By:
- Publication type:
- Article
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00541-0
- By:
- Publication type:
- Article
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-78221-9
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 777, doi. 10.1007/s40273-022-01145-7
- By:
- Publication type:
- Article
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.
- Published in:
- Journal of Cancer, 2023, v. 14, n. 7, p. 1151, doi. 10.7150/jca.81795
- By:
- Publication type:
- Article
Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
- Published in:
- Annals of Medicine, 2023, v. 55, n. 1, p. 1029, doi. 10.1080/07853890.2023.2186480
- By:
- Publication type:
- Article
Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.
- Published in:
- Annals of Medicine, 2023, v. 55, n. 1, p. 348, doi. 10.1080/07853890.2022.2164611
- By:
- Publication type:
- Article
Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
- Published in:
- Annals of Medicine, 2023, v. 55, n. 1, p. 388, doi. 10.1080/07853890.2022.2164610
- By:
- Publication type:
- Article
Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 12, p. 4883, doi. 10.1007/s00277-024-06117-9
- By:
- Publication type:
- Article
Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4497, doi. 10.1007/s00277-024-05845-2
- By:
- Publication type:
- Article
Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4033, doi. 10.1007/s00277-024-05923-5
- By:
- Publication type:
- Article
Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4309, doi. 10.1007/s00277-024-05922-6
- By:
- Publication type:
- Article
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4163, doi. 10.1007/s00277-024-05901-x
- By:
- Publication type:
- Article
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2993, doi. 10.1007/s00277-024-05775-z
- By:
- Publication type:
- Article
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 3053, doi. 10.1007/s00277-024-05738-4
- By:
- Publication type:
- Article